ACUR · As filed with the SEC
Acura Pharmaceuticals balance sheet, by fiscal year
The statement as Acura Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS · USD thousands
| USD thousands | FY2021 Dec 31, 2021 | FY2020 Dec 31, 2020 | FY2019 Dec 31, 2019 | FY2018 Dec 31, 2018 | FY2017 Dec 31, 2017 | FY2016 Dec 31, 2016 | FY2015 Dec 31, 2015 | FY2014 Dec 31, 2014 |
|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||
| Cash and cash equivalents | — | — | — | — | 2,220 | 2,681 | 2,485 | 774 |
| Restricted cash equivalents (Note 7) | — | — | — | — | 0 | 2,500 | — | — |
| Marketable securities (Note 5) | — | — | — | — | — | 0 | 10,837 | 11,322 |
| Trade accounts receivable (net of allowances of $- and $7) | — | — | — | — | 0 | 23 | 83 | 76 |
| Cash | 65,000 | 413,000 | 862,000 | 91,000 | — | — | — | — |
| Royalty receivable | 30,000 | 30,000 | 82,000 | 137,000 | 71,000 | 50,000 | — | — |
| Accrued investment income | — | — | — | — | — | 0 | 37 | 66 |
| Inventories (net of allowances of $- and $32) (Note 4) | — | — | — | — | 0 | 309 | 276 | 304 |
| Collaboration receivable from related party | 78,000 | 197,000 | 78,000 | — | 0 | 79,000 | — | — |
| License fees receivable from related party | 50,000 | 400,000 | — | — | — | — | — | — |
| Prepaid expenses and other current assets | 149,000 | 139,000 | 122,000 | 166,000 | 275,000 | 268,000 | 417,000 | 471,000 |
| Other current deferred assets | — | — | — | — | — | — | 0 | 218 |
| Income tax receivable | — | — | 34,000 | 67,000 | — | — | — | — |
| Total current assets | 372,000 | 1,179,000 | 1,178,000 | 461,000 | 2,566,000 | 5,910,000 | 14,135,000 | 13,231,000 |
| Income tax receivable | — | — | 34,000 | 68,000 | 135,000 | — | — | — |
| Finance lease right of use | 50,000 | — | — | — | — | — | — | — |
| Property, plant and equipment, net | 438,000 | 484,000 | 540,000 | 606,000 | 679,000 | 867,000 | 1,013,000 | 957,000 |
| Deferred debt issuance costs, net of accumulated amortization of $69 and $- (Note 8) | — | — | — | — | — | — | — | 162 |
| Intangible asset, net | 0 | 73,000 | 810,000 | 1,017,000 | 1,224,000 | 1,431,000 | 1,638,000 | 1,845,000 |
| Other assets | — | — | — | — | — | 0 | 175 | 0 |
| Total assets | 860,000 | 1,736,000 | 2,562,000 | 2,152,000 | 4,604,000 | 8,208,000 | 16,961,000 | 16,195,000 |
| Liabilities: | ||||||||
| Accounts payable | 192,000 | 31,000 | 237,000 | 605,000 | 3,000 | 77,000 | 110,000 | 217,000 |
| Accrued expenses | 238,000 | 631,000 | 585,000 | 596,000 | 939,000 | 703,000 | 564,000 | 568,000 |
| Accrued interest | — | — | — | 0 | 700,000 | — | 0 | 70,000 |
| Finance lease liability - current | 33,000 | — | — | — | — | — | — | — |
| Loans under CARES Act | 0 | 164,000 | — | — | — | — | — | — |
| Other current liabilities | 52,000 | 18,000 | 29,000 | 11,000 | 41,000 | 27,000 | 45,000 | 26,000 |
| Sales returns liability | — | 0 | 223,000 | 223,000 | 254,000 | 304,000 | 205,000 | — |
| Deferred revenue | — | — | — | — | — | — | 0 | 353 |
| Accrued interest to related party | 0 | 678,000 | — | — | — | — | — | — |
| Convertible debt to related party, net of discounts | 0 | 6,000,000 | — | 0 | 2,694,000 | 2,376,000 | 2,320,000 | 1,758,000 |
| Total current liabilities | 515,000 | 7,522,000 | 1,074,000 | 1,435,000 | 4,631,000 | 3,487,000 | 3,244,000 | 2,992,000 |
| Long-term debt, net of discount of $281 and $400 (Note 8) | — | — | — | — | — | — | — | 7,961 |
| Debt to related party, net of discounts (Note 7) | — | — | — | 4,224,000 | — | — | — | — |
| Convertible debt to related party, net of discounts (Note 7) | — | — | 6,000,000 | — | 0 | 2,979,000 | 5,430,000 | — |
| Accrued interest - non-current portion | — | — | — | — | 0 | 559 | 387 | 190 |
| Accrued interest to related party (Note 7) | — | — | 229,000 | 110,000 | — | — | — | — |
| Finance lease liability - noncurrent | 17,000 | — | — | — | — | — | — | — |
| Loans under CARES Act - noncurrent | 0 | 105,000 | — | — | — | — | — | — |
| Promissory note to related party | 150,000 | — | — | — | — | — | — | — |
| Total liabilities | 682,000 | 7,627,000 | 7,303,000 | 5,769,000 | 4,631,000 | 7,025,000 | 9,061,000 | 11,143,000 |
| Stockholders' equity (deficit): | ||||||||
| Common stock - $0.01 par value per share; 100,000 shares authorized, 65,093 and 21,650 shares issued and outstanding at December 31, 2021 and 2020, respectively | 651,000 | 216,000 | 213,000 | 210,000 | 208,000 | 118,000 | 118,000 | 488,000 |
| Additional paid-in capital | 389,610,000 | 383,097,000 | 383,042,000 | 380,395,000 | 380,145,000 | 375,763,000 | 375,157,000 | 366,898,000 |
| Accumulated deficit | (390,083,000) | (389,204,000) | (387,996,000) | (384,222,000) | (380,380,000) | (374,698,000) | (367,310,000) | (362,321,000) |
| Accumulated other comprehensive loss | — | — | — | — | — | 0 | (65) | (13) |
| Total stockholders' equity (deficit) | 178,000 | (5,891,000) | (4,741,000) | (3,617,000) | (27,000) | 1,183,000 | 7,900,000 | 5,052,000 |
| Total liabilities and stockholders' equity (deficit) | 860,000 | 1,736,000 | 2,562,000 | 2,152,000 | 4,604,000 | 8,208,000 | 16,961,000 | 16,195,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.